#United States #Franklin #Lynch Regenerative Medicine #GEM 21S #PDGF

Expansion of the Pure PDGF Portfolio at Lynch Regenerative Medicine

Lynch Regenerative Medicine, LLC (LRM), a key player in the field of regenerative medicine, has announced an exciting new partnership that will enhance its offerings in the regenerative space. The company has entered into a distribution agreement with Lynch Biologics, a division of Geistlich North America, to provide the innovative GEM 21S® product, an FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB), to licensed healthcare providers across the United States.

GEM 21S® signifies a significant addition to LRM’s Pure PDGF portfolio, which is already known for its therapeutic and aesthetic applications. Dr. Samuel Lynch, the founder and CEO of LRM, highlighted the robustness of GEM 21S®, referencing over 500 publications and nearly 100 clinical studies that support its safety and efficacy. This protein, which plays an essential role in natural healing and regenerative processes within the body, aligns with LRM's mission to transform scientific advancements into accessible regenerative solutions.

The collaboration with Geistlich, a global leader in oral regeneration, aims to broaden the reach of GEM 21S® and provide clinicians and patients with proven healing solutions. Dr. Lynch emphasized that this partnership will not be simply about introducing a single product but, rather, reinforcing a comprehensive regenerative medicine platform. The commitment to provide well-researched and reliable products is evident in LRM’s long-standing scientific approach to regenerative therapies.

By adding GEM 21S® to its repertoire along with products like REGRANEX® and ariessence pure PDGF+®, LRM is positioning itself as a frontrunner in PDGF-focused regenerative medicine. Known for its wide applicability, PDGF has been instrumental in improving the lives of millions of patients for over twenty years. The dual strategy not only focuses on therapeutic applications but also expands into cosmetic solutions, showcasing the versatility of PDGF-based therapies.

LRM aims to roll out GEM 21S® in the second quarter of 2026, with an eye toward introducing REGRANEX® Regranex Gel a few months later, depending on regulatory approvals and operational readiness. The establishment of LRM Aesthetics, Inc. and LRM Therapeutics, Inc. as two distinct arms of the company reflects LRM's dedication to both the aesthetic and therapeutic markets, enhancing its potential for targeted growth and development.

Dr. Lynch reiterated that LRM believes PDGF will remain a cornerstone of regenerative medicine for years to come. The company is committed to harnessing its proprietary manufacturing capabilities, intellectual assets, and advanced scientific insight to lead the market forward. By integrating multiple PDGF-based products, LRM not only mitigates risks associated with reliance on a singular product but strategically strengthens its overall market position.

In conclusion, Lynch Regenerative Medicine’s dedication to advancing regenerative solutions through innovative therapies and aesthetic enhancements positions it as an industry leader. With the addition of GEM 21S® and an expanded corporate structure, LRM is not only ready to meet the demands of healthcare providers but is also set to enhance patient outcomes through scientifically-backed products that foster healing and regeneration. For more information, interested parties can visit LynchRegen.com or contact LRM directly at 888-LRM-PDGF.